Skip to main content

Table 3 Estimated effects of prognostic parameters at the diagnosis of gynecological sarcoma in patients’ outcomes

From: Management of uterine sarcomas and prognostic indicators: real world data from a single-institution

Parameters

OS

Total number of patients = 61

HR (95%CI)

P-value

Adjusted HR (95%CI)

P-value

Elderly age

(> 65 vs. ≤65 years)

1.564

(0.690–3.545)

0.284

1.376

(0.583–2.764)

0.466

Advanced disease

(stage III/IV vs. I/II)

1.700

(0.982–3.114)

0.086

1.300

(0.641–2.636)

0.466

Tumor size

(> 10 cm vs. ≤10 cm)

1.418

(0.691–2.909)

0.341

1.403

(0.586–3.356)

0.447

Grade

(3 vs. 2/1)

2.144

(0.920–4.996)

0.077

1.758

(0.625–4.945)

0.285

Histological subtype

(LMS vs. Others)

0.968

(0.373–2.512)

0.947

0.989

(0.362–2.699)

0.982

Mitotic index

(>15mitoses/10HPF vs. ≤15mitoses/10HPF)

3.441

(1.649–7.181)

0.001

3.283

(1.426–7.559)

0.005

 

DFS

Total number of patients = 42

HR (95%CI)

P-value

Adjusted HR (95%CI)

P-value

Elderly age

(> 65 vs. ≤65 years)

1.404

(0.413–4.773)

0.586

0.671

(0.138–3.266)

0.621

Advanced disease

(stage III/IV vs. I/II)

1.267

(0.586–2.738)

0.547

0.970

(0.352–2.676)

0.953

Tumor size

(> 10 cm vs. ≤10 cm)

2.113

(0.853–5.235)

0.106

4.071

(1.205–13.752)

0.024

Grade

(3 vs. 2/1)

3.426

(1.014–11.569)

0.047

4.121

(0.927–18.326)

0.063

Histological subtype

(LMS vs. Others)

0.662

(0.263–1.667)

0.381

1.414

(0.410–4.874)

0.583

Mitotic index

(>15mitoses/10HPF vs. ≤15mitoses/10HPF)

2.687

(1.160–6.471)

0.028

3.041

(1.127–8.204)

0.028

Adjuvant regimen

(Antracycline-based vs. other chemotherapy)

0.783

(0.354–1.731)

0.546

0.555

(0.172–1.794)

0.325

 

1st line PFS

Total number of patients = 38

HR (95%CI)

P-value

Adjusted HR (95%CI)

P-value

Elderly age

(> 65 vs. ≤65 years)

1.300

(0.493–3.433)

0.596

0.927

(0.230–3.728)

0.915

Tumor size

(> 10 cm vs. ≤10 cm)

0.679

(0.303–1.522)

0.347

0.898

(0.270–2.986)

0.861

Grade

(3 vs. 2/1)

0.471

(0.188–1.181)

0.108

0.220

(0.047–1.032)

0.055

Histological subtype

(LMS vs. Others)

0.662

(0.263–1.667)

0.381

0.333

(0.087–1.282)

0.110

Mitotic index

(>15mitoses/10HPF vs. ≤15mitoses/10HPF)

1.158

(0.512–2.621)

0.752

1.463

(0.454–4.721)

0.524

Adjuvant chemotherapy

(Yes vs. no)

1.324

(0.635–2.762)

0.454

1.066

(0.337–3.375)

0.914

  1. Abbreviations: OS Overall survival, PFS Progression-free survival, HPF High power fields, OR Odd ratio, HR Hazard ratio, 95%CI 95% confidence intervals
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us